Allied Medicine Ltd.

A team of scientific, translational and clinical researchers pushing the boundaries of liquid biopsies in cancer. The team will deliver  an exquisitely sensitive cancer blood test which will facilitate best-in-class identification of minimal residual disease and cancer relapse, helping clinicians confidently establish responders and non-responders to existing and novel therapies.

The Team

Image

Harveer Dev

Radek Lach

About Me

I am a Group leader and academic urologist in the University of Cambridge Early Cancer Institute. My group studies the molecular basis of cancer, using genetic and epigenetic insights to define tumour-specific alterations that can be used for disease detection and therapeutic stratification.

Problem

Existing methods to track a person's response to cancer treatment can be inaccurate, invasive and expensive.

Solution 

To transform healthcare and expand drug eligibility through a high sensitivity low cost cancer-specific blood test.

Market

Healthcare providers and pharmaceutical companies looking for accurate ways to demonstrate response to existing and novel therapies, in standard of care and trial settings.

Contact

Harveer Dev LinkedIn 

Image